Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PI3K
    (20)
  • Apoptosis
    (2)
  • ATM/ATR
    (1)
  • Akt
    (1)
  • mTOR
    (1)
  • Others
    (10)
Filter
Search Result
Results for "

pi3kδ inhibitor 1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    32
    TargetMol | Inhibitors_Agonists
PI3kδ inhibitor 1
T124631332075-63-4
PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).
  • Inquiry Price
10-14 weeks
Size
QTY
Selective PI3Kδ Inhibitor 1
T58312088525-31-7
Selective PI3Kδ Inhibitor 1 is a PI3Kδ Inhibitor( IC50 = 0.9 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PI3Kγ inhibitor 1
T124641172118-03-4
PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.
  • Inquiry Price
6-8 weeks
Size
QTY
GS-9901
T154201640247-87-5In house
GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
  • Inquiry Price
6-8 weeks
Size
QTY
ATM Inhibitor-1
T103962135639-94-8
ATM Inhibitor-1 is a highly potent, selective, and orally active ATM inhibitor (IC50: 0.7 nM) with anti-tumor activity. It exhibits weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM), and PI3Kδ (IC50, 0.73 μM).
  • Inquiry Price
3-6 months
Size
QTY
Parsaclisib
INCB050465
T123671426698-88-5
Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)
  • Inquiry Price
Size
QTY
PI3K/mTOR Inhibitor-1
T124601949802-49-6
PI3K mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K mTOR (PI3Kα PI3Kβ PI3Kδ PI3Kγ mTOR with IC50s of 20 376 204 46 186 nM).
  • Inquiry Price
8-10 weeks
Size
QTY
PI3Kdelta inhibitor 1
T124612242109-74-4
PI3Kdelta inhibitor 1 is a potent, selective and orally available inhibitor of PI3Kδ with an IC50 of 1.3 nM.
  • Inquiry Price
6-8 weeks
Size
QTY
PI3Kδ-IN-1
T124621911564-39-0
PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).
  • Inquiry Price
8-10 weeks
Size
QTY
Parsaclisib hydrochloride
Parsaclisib HCl, INCB-50465, INCB 050465, INCB-050465, INCB050465 HCl, INCB 50465, INCB50465 HCl
T282971995889-48-9
Parsaclisib hydrochloride (INCB050465 HCl) is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM.
  • Inquiry Price
1-2 weeks
Size
QTY
(S)-PI3Kα-IN-4
(S)-PI3Kα-IN-4
T354882322293-84-3
(S)-PI3Kα-IN-4, a potent inhibitor of PI3Kα with an IC50 of 2.3 nM, demonstrates 38.3-, 4.25-, and 4.93-fold selectivity over PI3Kβ, PI3Kδ, and PI3Kγ, respectively, and is suitable for cancer research[1]. (S)-PI3Kα-IN-4 (compound 11) is a quinazolin-4(3H)-one derivative with 2-substituted-N-methylpropanamide substitution[1].
  • Inquiry Price
6-8 weeks
Size
QTY
FD223
T355312050524-24-6
FD223 is a potent, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor with a marked affinity (IC50=1 nM), demonstrating notable selectivity against other isoforms (IC50s: α=51 nM, β=29 nM, γ=37 nM). This compound effectively suppresses the proliferation of acute myeloid leukemia (AML) cell lines by inhibiting p-AKT Ser473, thereby inducing G1 phase cell cycle arrest. FD223 holds promise for leukemia research, particularly in AML[1].
  • Inquiry Price
6-8 weeks
Size
QTY
DS-7423
T360831222104-37-1
DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM and 34.9 nM for PI3Kα and mTOR, respectively, and exhibits anti-tumor activity[1][2]. It increases TP53 expression, the level of p-TP53 on Ser-46, and induces apoptosis-related TP53 target genes (TP53AIP1 and PUMA) in OCCC cells[1]. DS-7423 also inhibits other isoforms of class I PI3K with IC50 values of 1,143 nM for PI3Kβ, 249 nM for PI3Kγ, and 262 nM for PI3Kδ[2]. [1]. Katsutoshi Oda, et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res. 2016 Jul;42(7):757-62. [2]. Tomoko Kashiyama, et al. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
  • Inquiry Price
Size
QTY
pi3k/mtor inhibitor-9
T624381392421-71-4
PI3K mTOR Inhibitor-9 (Compound 1) is a potent inhibitor of both mTOR (IC50: 38 nM) and PI3K, including PI3Kα (IC50: 6.6 nM), PI3Kγ (IC50: 6.6 nM), and PI3Kδ (IC50: 0.8 nM).
  • Inquiry Price
6-8 weeks
Size
QTY
PI3K/AKT-IN-1
T629973033069-84-7
PI3K AKT-IN-1 is a dual PI3K and AKT inhibitor with anti-cancer activity. It inhibits PI3Kγ, PI3Kδ, and AKT, suppressing the PI3K AKT pathway and inducing caspase 3-dependent apoptosis, suitable for cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
pi3kδ/γ-in-3
T630782730151-31-0
PI3Kδ γ-IN-3 (Compound 58) is an orally active dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 16 nM), effective in inducing apoptosis of tumor cells and applicable to B-cell malignant tumor studies.
  • Inquiry Price
6-8 weeks
Size
QTY
pi3kδ/γ-in-2
T632212412195-89-0
PI3Kδ γ-IN-2 is a potent, orally bioavailable dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 4.3 nM), with potential for use in anti-B-cell malignancy studies.
  • Inquiry Price
6-8 weeks
Size
QTY
PI3Kδ/γ-IN-1
T634971980884-01-2
PI3Kδ γ-IN-1 is a selective and efficacious inhibitor of PI3Kδ γ, suitable for treating hematologic malignancies.
  • Inquiry Price
6-8 weeks
Size
QTY
umbralisib tosylate
TGR-1202 tosylate ; RP5264 tosylate, TGR-1202 tosylate, RP5264 tosylate
T724651532533-72-4
Umbralisib Tosylate (TGR-1202) is a potent, selectively dual inhibitor targeting PI3Kδ and casein kinase-1-ε (CK1ε), demonstrating oral activity. With EC50 values of 22.2 nM and 6.0 μM for PI3Kδ and CK1ε respectively, it shows unique immunomodulatory effects on T cells in chronic lymphocytic leukemia (CLL). This compound is utilized in the research of hematological malignancies.
  • Inquiry Price
6-8 weeks
Size
QTY
umbralisib sulfate
TGR-1202 sulfate ; RP-5264 sulfate, TGR-1202 sulfate, RP-5264 sulfate
T725271532533-75-7
Umbralisib (TGR-1202) sulfate, an orally active compound, serves as a potent, selective inhibitor targeting both PI3Kδ and casein kinase-1-ε (CK1ε), with EC50 values of 22.2 nM and 6.0 μM, respectively. It demonstrates unique immunomodulatory effects on T cells in chronic lymphocytic leukemia (CLL) and is applicable in the research of hematological malignancies.
  • Inquiry Price
6-8 weeks
Size
QTY
mek/pi3k-in-1
T743602281803-28-7
MEK PI3K-IN-1 (compound 6r) is a potent dual inhibitor of MEK and PI3K, exhibiting IC50 values of 124 nM for MEK1, 130 nM for PI3Kα, and 236 nM for PI3Kδ. It effectively reduces pAKT and pERK1 2 levels, demonstrating anti-proliferative effects on various tumor cell lines [1].
  • Inquiry Price
Size
QTY
mek/pi3k-in-2
T743612281803-33-4
MEK PI3K-IN-2 (compound 6s), a potent inhibitor of both MEK and PI3K, demonstrates IC50 values of 352 nM (MEK1), 107 nM (PI3Kα), and 137 nM (PI3Kδ), effectively reducing pAKT and pERK1 2 levels and exhibiting anti-proliferative activity against various tumor cell lines [1].
  • Inquiry Price
Size
QTY
PI3Kδ-IN-12
T78691
PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4 for PI3Kβ, and 6.7 for PI3Kα. This compound is used in researching chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD) [1].
  • Inquiry Price
Size
QTY
IHMT-PI3K-455
T78836
IHMT-PI3K-455 (Compound 15u) is a potent, selective PI3Kγ δ dual inhibitor with IC50 values of 7.1 nM for PI3Kγ and 0.57 nM for PI3Kδ, exhibiting oral activity. This compound inhibits AKT phosphorylation and promotes tumor regression by recruiting and activating CD8+ T cells. It is utilized in cancer research [1].
  • Inquiry Price
Size
QTY